Discontinued — last reported Q1 '18
Humana Allowance for Doubtful Accounts Receivable (Current) decreased by 5.6% to $102.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 15.7%, from $121.00M to $102.00M. Over 3 years (FY 2022 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 15.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.00M | $69.00M | $72.00M | $88.00M | $85.00M | $96.00M | $93.00M | $98.00M | $121.00M | $143.00M | $124.00M | $108.00M | $102.00M |
| QoQ Change | — | -1.4% | +4.3% | +22.2% | -3.4% | +12.9% | -3.1% | +5.4% | +23.5% | +18.2% | -13.3% | -12.9% | -5.6% |
| YoY Change | — | — | — | +25.7% | +23.2% | +33.3% | — | +11.4% | +42.4% | +49.0% | +33.3% | +10.2% | -15.7% |